Skip Main Links
Prescribing Information
Important Safety Information
For Healthcare
Providers
Sign Me Up

SODIUM IN XYWAV

XYWAV is the first and only low‑sodium* oxybate

*XYWAV contains 131 mg of sodium at the maximum recommended nightly dose.


Jump to:
  • How much sodium is in XYWAV?
  • XYWAV vs. XYREM
A woman discussing her sodium intake and her narcolepsy symptoms

If you’re considering an oxybate—either with stimulants or on its own—talk to your doctor about the high-sodium elephant in the room.

Ask about XYWAV, the only low-sodium option.

XYWAV has ~1509 mg less sodium per maximum recommended nightly dose than high-sodium oxybates

A bar graph comparing the sodium content of 9-g dose of XYREM/LUMRYZ (~1640 mg), 9-g dose of XYWAV (131 mg), and 4 large orders of fries (~1520 mg)

XYREM and LUMRYZ contain ~1,640 mg of sodium at the maximum recommended 9-g nightly dose.

Based on an average of 380 mg of sodium in 1 large serving of French fries according to a 2012 USDA analysis of 3 fast-food chains.

§XYWAV contains 131 mg of sodium at the maximum recommended 9-g nightly dose.

If you choose a high-sodium oxybate, such as XYREM® (sodium oxybate) oral solution or LUMRYZ (sodium oxybate) extended-release for oral suspension, you may go over the ideal daily sodium intake recommended by the American Heart Association without eating or drinking anything.

Transitioning from XYREM

Only XYWAV is clinically superior to XYREM, a high‑sodium oxybate, based on safety

XYWAV has ~1509 mg less sodium per night than XYREM at the maximum 9‑g nightly dose

Due to the reduction in sodium, the FDA determined XYWAV is clinically superior to XYREM by means of cardiovascular safety

According to the FDA the differences in sodium content between XYWAV and XYREM at recommended doses will be clinically meaningful in reducing cardiovascular diseases for many people with narcolepsy who suffer from cataplexy and/or EDS

Choosing XYWAV over high‑sodium oxybates, including the once‑nightly high‑sodium oxybate, reduces chronic sodium burden, which makes it the safer option.

A clinical trial comparing the efficacy and safety of XYWAV and LUMRYZ has not been conducted.

The decision of the FDA Office of Orphan Product Development (OOPD) is based on findings that XYWAV provides a greatly reduced chronic sodium burden compared to XYREM. There are no head-to-head data for XYWAV and XYREM.

XYWAV has 131 mg of sodium per maximum recommended 9-g nightly dose, while the equivalent dose of high-sodium oxybate XYREM contains ~1640 mg—a difference of ~1509 mg every single day.

Wondering if an oxybate treatment like low-sodium XYWAV might be right for you?

Take the Quiz
Up Arrow Icon
Sign Me Up

This site is intended for US residents only.

© 2024 Jazz Pharmaceuticals, Inc. US-XYW-2200245 Rev1124